SAN DIEGO and LEXINGTON, Mass., Dec.
9, 2014 /PRNewswire/ -- Shareholder rights attorneys at
Robbins Arroyo LLP are investigating the proposed acquisition of
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) by Merck & Co.,
Inc. (NYSE: MRK). On December 8,
2014, the two companies announced the signing of a
definitive merger agreement pursuant to which Merck will acquire
Cubist Pharmaceuticals. Under the terms of the agreement,
Cubist Pharmaceuticals shareholders will receive $102 for each share of Cubist Pharmaceuticals
common stock.
View this information on the law firm's Shareholder Rights Blog:
http://www.robbinsarroyo.com/shareholders-rights-blog/cubist-pharmaceuticals-inc
Is the Proposed Acquisition Best for Cubist
Pharmaceuticals and Its Shareholders?
Robbins Arroyo LLP's investigation focuses on whether the board
of directors at Cubist Pharmaceuticals is undertaking a fair
process to obtain maximum value and adequately compensate its
shareholders.
On October 21, 2014, Cubist
Pharmaceuticals released its earnings results for its third quarter
2014, reporting strong quarterly earnings. Total net revenues for
the third quarter fiscal 2014 were $309.2
million, up 16% compared to $266
million for the comparable quarter in fiscal 2013.
Additionally, international product revenues were $16.6 million compared to $13.0 million in third quarter 2013. In
commenting on these results, Cubist Pharmaceuticals Chief Executive
Officer Mike Bonney remarked, "This
was a strong quarter for Cubist in which we made significant
progress against our 2014 financial and business objectives, driven
by CUBICIN and meaningful contributions across our portfolio.…
Third quarter results reflect important momentum across our
portfolio and complement our continued launch preparation leading
up to the December FDA action date of our potential blockbuster
ceftolozane/tazobactam, now known as ZERBAXA."
In light of these facts, Robbins Arroyo LLP is examining Cubist
Pharmaceuticals' board of directors' decision to sell the company
now rather than allow shareholders to continue to participate in
the company's continued success and future growth prospects.
Cubist Pharmaceuticals shareholders have the option to file a
class action lawsuit to ensure the board of directors obtains the
best possible price for shareholders and the disclosure of material
information. Cubist Pharmaceuticals shareholders interested in
information about their rights and potential remedies can contact
attorney Darnell R. Donahue at (800)
350-6003, ddonahue@robbinsarroyo.com, or via the shareholder
information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in
securities litigation and shareholder rights law. The law
firm represents individual and institutional investors in
shareholder derivative and securities class action lawsuits, and
has helped its clients realize more than $1
billion of value for themselves and the companies in which
they have invested.
Attorney Advertising. Past results do not guarantee a
similar outcome.
Contact:
Darnell R. Donahue
Robbins Arroyo LLP
600 B Street, Suite 1900
San Diego, CA 92101
ddonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com
Logo -
http://photos.prnewswire.com/prnh/20130103/MM36754LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acquisition-of-cubist-pharmaceuticals-inc-cbst-by-merck--co-inc-mrk-may-not-be-in-shareholders-best-interests-300007486.html
SOURCE Robbins Arroyo LLP